Anixa Biosciences (ANIX) Notes Payables (2013 - 2014)
Anixa Biosciences' (ANIX) quarterly Notes Payables came in at $1.0 million in Q4 2014, up 91.11% YoY from $540000.0 in Q4 2013, and down 45.68% on a QoQ basis from $1.9 million in Q3 2014.
Anixa Biosciences (ANIX) Notes Payables (2013 - 2014) Analysis & Trends
Anixa Biosciences (ANIX) has 2 years of Notes Payables data on file, last reported at $1.0 million in Q4 2014.
- Quarterly Notes Payables rose 91.11% year-over-year to $1.0 million in Q4 2014, while the trailing twelve-month figure through Oct 2014 was $1.0 million (up 91.11% YoY) and the FY2014 annual result came in at $1.0 million, up 91.11% from the prior year.
- Notes Payables eased to $1.0 million in Q4 2014, from $1.9 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $3.4 million in Q1 2014 to a low of $540000.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - |
| 10 | Anixa Biosciences | 125.31 Mn | 125.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2014 | 1.03 Mn |
| Jul 31, 2014 | 1.90 Mn |
| Jan 31, 2014 | 3.43 Mn |
| Oct 31, 2013 | 540,000.00 |
| Jul 31, 2013 | 700,000.00 |
| Apr 30, 2013 | 970,000.00 |
| Jan 31, 2013 | 1.18 Mn |